| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Valneva SE | VLA15 - (VALOR) | Lyme disease vaccine for outdoor recreationists | Phase 3 | Ongoing | Intramuscular | Immunology |
| Valneva SE | VLA15-221 | Lyme disease | Phase 3 | Data Released | Intramuscular | Antibiotic |
| Valneva SE | IXCHIQ (VLA1553-221) - (adolescents trial) | Chikungunya vaccine | Phase 3 | Trial Planned | Subcutaneous | N/A |
| Valneva SE | S4V Shigella Vaccine - (CHIM study) | Shigella | Phase 2b | Ongoing | oral | N/A |
| Valneva SE | S4V Shigella Vaccine - (CHIM study) | Shigella | Phase 2b | Ongoing | oral | N/A |
| Valneva SE | S4V02 | Tetravalent Shigella Vaccine | Phase 2 | Ongoing | Subcutaneous | N/A |
| Valneva SE | S4V Shigella vaccine - (LMIC trial) | Shigella | Phase 2 | Trial Planned | Oral | N/A |
| Vanda Pharmaceuticals Inc. | Bysanti (milsaperidone) | Acute bipolar I disorder | PDUFA | Ongoing | Oral | Psychiatric |